DOI: https://doi.org/10.22141/2309-8147.5.1.2017.172571

DISTRIBUTION OF GENOTYPES AND ASSOCIATION OF GENE VEGFA POLYMORPHISMS (rs2010963 & rs699947) WITH DIABETIC RETINOPATHY IN DIABETES MELLITUS TYPE 2

A. S. Hudz, G. E. Zakharevich

Abstract


Summary. Defi nition of genetic polymorphisms importance of VEGFA rs2010963 (–634 G/C) and rs699947 (–2578c> A) with the diabetic retinopathy (DR) in diabetes mellitus type 2 was the purpose of this research. Patients (n=302) were distributed into three groups: 1st group (n=98) – patients who had no diabetes mellitus and retinopathy (control); 2nd group (n=140) – patients without proliferative DR, and 3rd group (n=64) – patients diagnosed with proliferative DR. The analysis of DNA loci was carried out with the use of TaqMan Mutation Detection Assays Thermo Fisher Scientifi c (USA) in automatic Real-Time PCR System 7500 (Applied Biosystems, USA). With the development of non-proliferative DR the association (p(χ2)=0,03) at rs2010963 was traced: the ancestral G allele decreased the risk of development (OR=0,62; 95 % СІ 0,42–0,95), and the minor allele – increased the risk (OR=1,59; 95 % СІ 1,05–2,41). With the development of proliferative DR, correlation was traced also for genotypes (p(χ2)=0,002), and for alleles (p(χ2)=2,0E–04) rs2010963. The G allele decreased the risk (OR=0,41; 95 % СІ 0,25–0,66), and C allele – increased the risk (OR=2,45; 95 % СІ 1,51–3,97). Also, the development of proliferative DR is associated with rs699947: the ancestral allele C increased the risk (OR=1,82; 95 % СІ 1,15–2,89), and the minor A allele decreased the risk (OR=0,55; 95 % СІ 0,35–0,87). The homozygote C/C increased the risk (OR=2,68; 95 % СІ 1,28–5,65) whereas the minor homozygote A/A – considerably decreased the risk (OR=0,11; 95 % СІ 0,01–0,90).

Keywords


diabetic retinopathy, diabetes mellitus 2 types, VEGFA, rs2010963, rs699947

References


Дедов И. И. Диабетическая ретинопатия: современные проблемы / И. И. Дедов, О. М. Смирнова // Сахарный диабет. – 2008. – № 3. – С. 4–8.

Коненков М. И. Ангиогенез при пролиферативной диабетической ретинопатии: перспективы анти-VEGF-терапии / В. И. Коненков, В. В. Климонтов, В. В. Черных, Н. В. Тян // Офтальмохирургия. – 2013. – № 4. – С. 111–115.

Сарыгина О. И. Роль сосудистого эндотелиального фактора роста в патогенезе диабетической ретинопатии / О. И. Сарыгина, В. В. Нероев, O. A. Левкина // Вестник офтальмологии. – 2009. – № 2. – С. 58–60.

Abouammoh M. A. Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review / M. A. Abouammoh // Can. j. ophthalmol. – 2013. – Vol. 48, № 4. – P. 317–323.

Bloomgarden Z. Screening for and managing diabetic retinopathy: current approaches / Z. Bloomgarden //Am. j. health syst. pharm. – 2007. – Vol. 64, № 17 (suppl. 12). – P. s8–s14.

Bonnefond A. What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications? / A. Bonnefond, P. J. Saulnier, M. G. Stathopoulou [et al.] // PloS one. – 2013. – Vol. 8, № 2. – e55921.

Buraczynska M. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients / M. Buraczynska, P. Ksiazek, I. Baranowicz-Gaszczyk, L. Jozwiak // Nephrology dialysis transplantation. – 2007. – Vol. 22, № 3. – P. 827–832.

Standards of medical care in diabetes – 2012 / American Diabetes Association // Diabetes care. – 2012. – Vol. 35 (suppl. 1). – P. s11–s63.

Fleming A. D. The evidence for automated grading in diabetic retinopathy screening / A. D. Fleming, S. Philip, K. A. Goatman [et al.] // Curr. diabetes rev. – 2011. – Vol. 7, № 4. – P. 246–252.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта